As a result, our studies include patients with lung cancer with wild-type and mutant EGFR. We thus alternatively used EGFR-TKI responders as a surrogate for EGFR mutations, which are associated with a favorable response to EGFR-TKI therapy. Here, EGFR is linked to lung carcinoma.